PreveCeutical Medical Inc. PREV
CNSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -4.83% | 132.17% | 345.24% | 185.80% | 165.70% |
| Depreciation & Amortization | 27.27% | 44.16% | 39.19% | 28.38% | 20.55% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.55% | 134.41% | 322.81% | 175.28% | 148.50% |
| Operating Income | 0.55% | -134.41% | -322.81% | -175.28% | -148.50% |
| Income Before Tax | 69.96% | 11.63% | -41.22% | -124.30% | -100.03% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 69.96% | 11.63% | -41.22% | -124.30% | -100.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 159.86% | -- | -- | -- | -- |
| Net Income | 73.65% | 20.34% | -28.88% | -121.34% | -96.86% |
| EBIT | 0.55% | -134.41% | -322.81% | -175.28% | -148.50% |
| EBITDA | 0.70% | -135.20% | -326.68% | -176.79% | -149.93% |
| EPS Basic | 75.76% | 26.09% | -25.00% | -105.26% | -94.12% |
| Normalized Basic EPS | 0.00% | -78.57% | -170.00% | -100.00% | -81.82% |
| EPS Diluted | 75.76% | 26.09% | -25.00% | -105.26% | -94.12% |
| Normalized Diluted EPS | 0.00% | -78.57% | -170.00% | -100.00% | -81.82% |
| Average Basic Shares Outstanding | 8.93% | 9.01% | 5.94% | 3.23% | 1.67% |
| Average Diluted Shares Outstanding | 8.93% | 9.01% | 5.94% | 3.23% | 1.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |